Please login to the form below

Not currently logged in
Email:
Password:

Suboxone

This page shows the latest Suboxone news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Indivior’s drug to fight opioid addiction

FDA panel backs Indivior’s drug to fight opioid addiction

That would help counteract a major setback for the business in the US a few weeks back when it lost a patent infringement lawsuit involving its main product Suboxone (buprenorphine and ... RBP-6000 is a long-acting form of buprenorphine that can be

Latest news

  • Indivior slumps as patent dispute rises US generic spectre Indivior slumps as patent dispute rises US generic spectre

    The UK-listed company - which was spun out of Reckitt Benckiser three years ago - generates the bulk of its revenues from Suboxone (buprenorphine and naloxone), an oral film product used for ... As it stands, those two companies remain blocked from

  • Reckitt to spin-off pharma unit as Indivior Reckitt to spin-off pharma unit as Indivior

    Reckitt to spin-off pharma unit as Indivior. Demerged business will focus on opioid dependence product Suboxone. ... RBP generates nearly all its revenues from Suboxone (buprenorphine and naloxone), used for the treatment of opioid dependence, and -

  • Reckitt Benckiser confirms pharma spin-off plans Reckitt Benckiser confirms pharma spin-off plans

    The pharma unit generates nearly all its revenues from Suboxone (buprenorphine and naloxone), used for the treatment of opioid dependence, and - while prescription volumes for the product grew in the US - ... RB Pharma is trying to expand its product

  • Reckitt Benckiser may spin out pharma division Reckitt Benckiser may spin out pharma division

    Reckitt's main pharmaceutical product is Suboxone (buprenorphine and naloxone) for the treatment of opioid dependence, which has been under pressure thanks to an increasingly competitive market space, and revenues for ... One reason for the decline is

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    Indivior will not be without its challenges as sales of its off-patent opioid addiction treatment Suboxone continue to slump.

  • Pharma deals during July 2014 Pharma deals during July 2014

    However, with revenues falling by 8 per cent in H1 2014 as a result of US generic competition for Suboxone (the pharma unit's top selling drug), it remains to be

  • Pharma deals during May 2014 Pharma deals during May 2014

    All options continue to be considered. A capital markets solution is emerging as a strong option.” The difficulty is that Suboxone (for treatment of drug addiction) sales are being hit by

  • Pharma deals during February 2013 Pharma deals during February 2013

    November 2012 may distract attention from the noise surrounding the Suboxone film versus tablets debate.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics